|
시장보고서
상품코드
2039137
피라지나미드 시장 : 환자 유형별, 유통 채널별, 지역별Pyrazinamide Market, By Patient Type (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) |
||||||
피라지나미드 시장은 2026년에 75억 3,000만 달러로 추정되고 있으며, 2033년까지 172억 3,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.9%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 75억 3,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 10.90% | 예측 금액(2033년) | 172억 3,000만 달러 |
피라지나미드(PZA)는 결핵 치료에 사용되는 약물입니다. 또한 활동성 결핵의 경우 리팜피신, 이소니아지드, 스트렙토마이신 또는 에탐부톨과 병용하는 경우가 많습니다. 일반적으로 잠복결핵 치료에는 권장하지 않습니다. 피라지나미드는 다른 결핵 치료제로는 사멸시킬 수 없는 비번식성 지속성 결핵균을 사멸시키기 때문에 약제 감수성 결핵이나 다제내성 결핵(MDR-TB) 등의 치료에 있으며, 모든 약제 병용요법에 필수적인 약제입니다. 피라지나미드는 지속균의 생존에 필요한 에너지 생산, 번역 및 보효소 A를 억제함으로써 다른 항생제와는 다른 작용기전을 보입니다. 약물 표적 유전자의 돌연변이가 증가함에 따라 PZA에 대한 내성이 더 강한 균주가 출현하고 있습니다. 최근 내성균주에서 pncA, rpsA 돌연변이 유전자와 함께 panD 돌연변이 유전자가 확인되었습니다.
시장 역학
결핵의 큰 부담이 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 세계보건기구(WHO)에 따르면 2017년 신규 결핵 환자의 87%가 결핵 발병률이 높은 30개국에서 발생했습니다. 이 30개국 중 8개국(인도, 중국, 인도네시아, 필리핀, 파키스탄, 파키스탄, 나이지리아, 나이지리아, 방글라데시, 남아프리카공화국)이 신규 결핵 발생의 3분의 2를 차지합니다.
전 세계 결핵 부담 증가는 피라지나미드 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 미국 질병예방통제센터(CDC)에 따르면 2017년 전 세계에서 1,000만 명이 결핵에 걸렸으며, 결핵 관련 사망자는 전 세계에서 130만 명에 달했습니다.
또한 2018년 발표된 WHO 자료에 따르면 결핵으로 인한 전 세계 연간 비용은 210억 달러에 달하며, 이 중 92억 달러는 치료와 예방에, 120억 달러는 추가 경제적 비용과 생산성 손실에 사용됩니다. 따라서 결핵 치료에 대한 의료비 증가가 시장 성장을 촉진할 것으로 예상됩니다.
또한 WHO에 따르면 다제내성 결핵(MDR-TB) 치료에는 20-26개월이 소요되며, 미국내 평균 치료비용은 약 29만 4,000달러에 달합니다.
또한 결핵 치료를 위한 새로운 치료제 개발을 위한 연구개발(R&D) 활동에 대한 투자 증가는 피라지나미드계 약제 시장의 성장을 억제할 것으로 예상됩니다. 예를 들어 '결핵 연구 자금 동향 2005-2017' 보고서에 따르면 2017년 결핵 연구에 대한 전 세계 투자액은 7억 7,200만 달러로 2016년 7억 2,600만 달러에 비해 6%(4,600만 달러) 증가한 것으로 평가되었습니다.
이 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 세계 피라지나미드(Pyrazinamide) 시장의 주요 기업 개요을 각종 파라미터(기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 동향 및 전략 등)에 따라 정리하여 전해드립니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계의 피라지나미드 시장" 보고서는 불임치료제 및 의료기기 분야의 투자자, 제조업체, 유통업체, 공급업체, 연구 및 컨설팅 회사, 신규 참가자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 피라지나미드 시장 : 환자 유형별(2021-2033년)
제5장 세계의 피라지나미드 시장 : 유통 채널별(2021-2033년)
제6장 세계의 피라지나미드 시장 : 지역별(2021-2033년)
제7장 경쟁 구도
제8장 애널리스트의 제안
제9장 참고 문헌 및 분석 방법
KSA 26.06.05Pyrazinamide Market is estimated to be valued at USD 7.53 Bn in 2026 and is expected to reach USD 17.23 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.53 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.90% | 2033 Value Projection: | USD 17.23 Bn |
Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.
Market Dynamics
The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.
The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.
Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
- It profiles key players in the global pyrazinamide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- By Patient Type (Revenue, USD Bn, 2021-2033)
- Adult
- Pediatric
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Pyrazinamide Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Pure Chemistry Scientific
- LGM Pharma
- TCI
- HBCChem
- Alfa Chemistry
- Toronto Research Chemicals
- Acros Organics
- AlliChem
- Waterstone Technology
- City Chemical
- EDQM
- J & K SCIENTIFIC
- Meryer (Shanghai) Chemical Technology
- Energy Chemical
- Beijing Ouhe Technology
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pyrazinamide Market, By Patient Type
- Global Pyrazinamide Market, By Distribution Channel
- Global Pyrazinamide Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Pyrazinamide Market, By Patient Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Pyrazinamide Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Pyrazinamide Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Pure Chemistry Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LGM Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- TCI
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- HBCChem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alfa Chemistry
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Toronto Research Chemicals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acros Organics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AlliChem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Waterstone Technology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- City Chemical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EDQM
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- J & K SCIENTIFIC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Meryer (Shanghai) Chemical Technology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Energy Chemical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beijing Ouhe Technology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
8. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. References and Research Methodology
- References
- Research Methodology
- About us
